You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Dow
Express Scripts
Colorcon
McKinsey

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

Details for Biologics License Application: 125370

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for BLA: 125370
Tradename:BENLYSTA
Applicant:Human Genome Sciences Inc.
Ingredient:belimumab
Patents:51
Approval Date:Mar 09, 2011
Suppliers: see list1
Pharmacology for BLA: 125370
Drug ClassB Lymphocyte Stimulator-specific Inhibitor
Mechanism of ActionB Lymphocyte Stimulator-directed Antibody Interactions
Physiological EffectDecreased B Lymphocyte Activation

US Patents for BLA: 125370

Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) 2039-02-26 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial Exagen Diagnostics, Inc. (Vista, CA) 2031-02-11 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial UBE INDUSTRIES, LTD. (Yamaguchi, JP) 2036-04-28 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial CMC BIOLOGICS A/S (Soborg, DK) 2033-03-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
Harvard Business School
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group